M
ortality among persons living with HIV (PLWH) has been drastically reduced by treatment with effective antiretroviral therapy (ART), which suppresses HIV replication and improves immune function (1) . Persons newly diagnosed with HIV in North America are expected to live to their early 70s with treatment (2) . This increased longevity has shifted the age distribution of U.S. PLWH from 27% aged 50 years or older in 2006 to 45% in 2014 (3, 4) , and the fraction of older PLWH is expected to continue growing. Antiretroviral therapy has also reduced the risk for certain types of cancer known to occur in excess among PLWH, particularly AIDS-defining cancer (ADC) (that is, Kaposi sarcoma [KS] , certain types of nonHodgkin lymphoma [NHL] , and cervical cancer) (5, 6) . The decrease in ADC rates combined with the growth and aging of the U.S. HIV population has resulted in a shift from predominantly ADC in the 1980s (7) to predominantly non-AIDS-defining cancer (NADC) in 2010 and a net increase in incident cancer diagnoses (that is, cancer burden) over time (8) . The most frequent types of NADC in PLWH include those that occur at a higher rate among PLWH (such as anal cancer, liver cancer, oral cavity and pharyngeal cancer, and Hodgkin lymphoma [which are caused by viral co-infections] and lung cancer) and those that are common in the general population (such as prostate, breast, and colon cancer) (8) .
The cancer burden among U.S. PLWH will continue to evolve as cancer incidence rates and the size and demographics of the HIV population change over time. We used population-based data on HIV and cancer to project cancer incidence rates in the adult HIV population and the HIV Optimization and Prevention Economics (HOPE) model to forecast the number of PLWH through 2030. We then calculated projected cancer burden. These results highlight anticipated reductions in cancer burden with continued and expanded access to ART and identify types of cancer expected to predominate in the future, informing public health research and the prioritization of cancer prevention, early detection, and treatment. tries in 9 U.S. regions (www.hivmatch.cancer.gov). This analysis considered the most common cancer types among PLWH: KS; NHL; Hodgkin lymphoma; and cervical, anal, lung, liver, oral cavity and pharyngeal, prostate, breast, and colon cancer (9) , classified on the basis of the International Classification of Diseases for Oncology, Third Edition (10) . All other cancer sites were analyzed together as "other types of cancer. " We modeled trends in cancer incidence rates during 2000 to 2012 to project rates during 2013 to 2030. Follow-up began on 1 January 2000, the beginning of cancer registry coverage, or the first of HIV report date or AIDS diagnosis date, whichever occurred last. It ended at either death or the end of cancer registry coverage. Cancer incidence rates among adults were estimated in strata defined by calendar year and age group ( Table 1 , available at Annals.org). Children and (for some cancer sites) younger adults were excluded because cancer in these groups was too rare to model. We used joinpoint regression (11) to identify statistically significant changes in the slope of time trends (that is, joinpoints). We identified 3 cancer incidence trends with significant joinpoints. For NHL, we restricted our analysis to years after the joinpoint (2002 and later). However, because follow-up data were limited for anal cancer in MSM (joinpoint, 2009) and liver cancer in PWID (joinpoint, 2005), we used 2000 to 2012 to analyze these cancer sites (Appendix, available at Annals.org).
We used Poisson regression to estimate the annual change in cancer incidence rates during 2000 to 2012. Estimated ␤-coefficients and variance-covariance matrixes were then used to project cancer incidence rates and 95% CIs for 2013 to 2030. Age group was included as a term in the model unless a significant interaction (P ≤ 0.10) between age group and calendar year was present, in which case age group-specific models were estimated. If no statistically significant trend was observed during 2000 to 2012, modeled 2012 rates were applied for 2013 to 2030. For cancer types known to be elevated in PLWH, we assumed a priori that future cancer rates would never be lower than those observed in the general population. Therefore, for these cancer types, any projected rate that was lower than the 2013 age-specific rate in the SEER-18 (Surveillance, Epidemiology, and End Results-18) data (12) (used as a proxy for the U.S. general population) was reset to the SEER rate. Likewise, because PLWH have a lower risk for prostate, breast, and colon cancer for unclear reasons (9, 13), we assumed that the age-specific rates of these cancer types would never exceed those in SEER-18 (Appendix). Rates standardized by age (and by risk group for KS, anal cancer, and liver cancer) were estimated for 2006 to 2030 by standardizing each year to the 2010 modeled HIV population (see below). 
HIV Population Estimates

Cancer Burden Projections
The number of incident cancer diagnoses (that is, cancer burden) per calendar year was estimated by multiplying incidence rates specific to age and risk groups by numbers of PLWH in corresponding strata. Uncertainty estimates were generated by multiplying the lower and upper 95% CIs from the incidence rates by the minimum and maximum numbers of PLWH, respectively (Appendix).
We compared the cancer burden estimates in 2030 in 2 scenarios: assuming a flat projection of the 2012 cancer incidence rates and assuming that the age distribution (but not population size) in 2030 remained the same as in 2012. These approaches provide insight into the independent effects that changing cancer incidence rates and age structure of the HIV population have on the estimated burden.
For comparison, we also present the proportion of the total cancer burden contributed by each cancer site among PLWH during 2010 and 2030 and in the general U.S. population in 2010, with data from SEER-18.
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RESULTS
Cancer Incidence Rates Among Adult PLWH, 2000 to 2030
Between 2000 and 2012, a total of 23 907 cases of cancer occurred among 463 300 HIV-infected adults in the HIV/AIDS Cancer Match Study. During that time, observed incidence rates decreased significantly (P < 0.05) for KS, NHL, cervical cancer, anal cancer (among MSM), lung cancer, Hodgkin lymphoma, and other cancer types across all age groups and for colon cancer among only those aged 65 years or older. Incidence rates of NHL, cervical cancer, and lung cancer are projected to decrease to the general population rates for some age groups (Appendix Table 1 and Appendix Figure 1 , available at Annals.org). Prostate cancer rates increased significantly among men aged 35 to 44 years and 45 to 64 years, reaching general population rates, but not among men aged 65 years or older. No significant trends (P ≥ 0.05) were observed across age groups for rates of anal cancer among non-MSM, liver cancer among PWID and non-PWID, oral cavity and pharyngeal cancer, and breast cancer, or among those aged 25 to 64 years for rates of colon cancer (Appendix Table 1 ).
Age-standardized incidence rates are projected to decrease during 2006 to 2030 for 7 of 11 cancer sites. This includes all 3 types of ADC and 4 of 8 types of NADC but excludes breast, oral cavity and pharyngeal, and liver cancer, for which rates are expected to remain stable, and prostate cancer, for which rates will increase ( Figure 1) . We project the largest relative declines (approximately 80%) in age-standardized incidence rates per 100 000 PLWH for KS (129.8 to 29.0 cases), NHL (184.3 to 36.1 cases), and cervical cancer (61.0 to 10.2 cases).
Estimated Number of Adult PLWH, 2006 to 2030
The number of adult PLWH in the United States is projected to increase from 1.06 million in 2006 to 1.17 million in 2018 before decreasing to 1.09 million in 2030 ( Figure 2 ). This projected decrease is caused by declines in HIV incidence rates due to reduced transmission resulting from increases in the proportion of PLWH who know they are infected, receive effective treatment, and are virally suppressed (15) . Of note, the age distribution of PLWH is expected to shift substantially between 2010 and 2030: The proportion of adult PLWH aged 65 years or older will nearly triple from 8.5% to 21.4%, and the proportion aged 45 to 64 years will increase from 39.4% to 47.7% (Appendix Table 2 , available at Annals.org). The sex and racial/ethnic distributions are expected to remain roughly the same, and the fraction of adult PLWH who are MSM is projected to increase slightly (from 55.4% in 2010 to 61.0% in 2030). Appendix Table 3 (available at Annals.org) gives the minimum and maximum HIV population estimates for each calendar year.
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Estimated Cancer Burden Among Adult PLWH, 2006 to 2030
In 2010, PLWH had an estimated 8150 cancer cases (uncertainty estimate, 7280 to 9210 cases), including 2730 of ADC (uncertainty estimate, 2440 to 3100 cases) and 5420 of NADC (uncertainty estimate, 4850 to 6120 cases) (Table) . The total is expected to decrease to 6690 cases (uncertainty estimate, 4950 to 9060 cases) in 2030, driven by strong decreases in ADC but with modest increases in NADC (Figure 3) . When examined by age, 1500 fewer cases are expected among PLWH younger than 45 years and 40 additional cases among PLWH aged 45 years or older in 2030 compared with 2010 ( Figure 3) .
The composition of the cancer burden is expected to shift substantially over time ( Figure 4) . The largest decreases between 2010 and 2030 are estimated to occur for NHL (Ϫ1040 cases) and KS (Ϫ880 cases) and the largest increases for prostate (+840 cases), lung (+200 cases), and liver cancer (+120 cases). The expected cancer burden in 2030 among PLWH will remain different from the observed burden in the general population in 2010, with a higher fraction of liver cancer, anal cancer, and KS (Appendix Figure 2 , available at Annals.org).
Influence of Cancer Incidence Rates and the Aging of the HIV Population on Cancer Burden
To assess the independent effect of changing incidence rates on cancer burden, we estimated the burden for 2030 using the generally higher 2012 incidence rates (fixing the HIV population demographics to the 2030 projection). The burden estimates produced by the 2012 rates were 43% higher than those projected in the main analysis, including a 197% increase in ADC and a 24% increase in NADC ( Figure 5 ). This pattern held for most cancer types, except for breast, liver, and oral cavity and pharyngeal cancer (that is, types that already had flat incidence projections) and prostate cancer. The largest differences in burden were observed for NHL and KS.
To assess the independent effect of aging of the HIV population, we estimated the 2030 cancer burden using the generally younger age structure of the 2012 population (fixing the cancer incidence rates at the Cancer Projections in HIV-Infected U.S. Adults Through 2030 ORIGINAL RESEARCH 2030 projections). Compared with the results from the main analysis, the cancer burden in 2030 would be 25% lower if the 2012 age structure were used. The total number of NADC cases would be 28% lower, whereas the total number of ADC cases would be 3% higher. Decreases in burden were seen for most cancer types except for cervical cancer, Hodgkin lymphoma, and KS; prostate and lung cancer had the largest decreases ( Figure 5 ).
DISCUSSION
Increased life expectancy among PLWH due to effective ART will result in further aging of the HIV population in the coming years. Concurrently, if recent trends in cancer incidence rates among PLWH continue, the incidence rates of many types of cancer will decrease through 2030; the largest declines are predicted for the 2 most common ADC types, NHL and KS. As a result, we forecast notable shifts in the number of incident cancer diagnoses (that is, cancer burden) among PLWH in the coming decade. The fraction of the cancer burden due to ADC will decrease from one third in 2010 to 11% in 2030, and the most common cancer types diagnosed among PLWH will shift from NHL and KS in 2010 to prostate and lung cancer in 2030.
Antiretroviral therapy has been the most effective means of reducing cancer burden in PLWH and will continue to be critical in the future. It suppresses HIV replication and reduces immunosuppression among PLWH, improving the immune system's ability to control oncogenic viral infections (18) . Because most types of ADC are caused by viral co-infections (that is, human herpesvirus-8 causes KS, Epstein-Barr virus causes some types of NHL, and human papillomavirus [HPV] causes cervical cancer), ART has been particularly effective at reducing ADC incidence (5, 6, 19) . If progress continues, ADC rates for all ages will continue to decrease, and rates of NHL (in older age groups) and cervical cancer will converge with those of the general population before 2030. Although KS and NHL rates in younger age groups will remain higher than those of the general population, declining rates will lead to a notable decrease in the number of these cancer cases through 2030.
The risks for anal, lung, liver, and oral cavity and pharyngeal cancer and Hodgkin lymphoma are elevated among PLWH compared with the general population (20, 21) . Increased risk is likely driven by a combination of factors. First, PLWH have a higher burden of certain carcinogenic viruses, such as HPV and hepatitis B and C viruses. In addition, lack of viral control in the setting of immunosuppression increases cancer risk (that is, HPV causes anal cancer and some types of tonsil and oropharyngeal cancer, hepatitis B and C viruses cause liver cancer, and Epstein-Barr virus causes Hodgkin lymphoma). Finally, PLWH have a higher prevalence of some cancer risk factors, most notably cigarette smoking (18, 22) . Of note, elevated risk for lung cancer is not entirely explained by smoking, and immune suppression, chronic lung inflammation-pulmonary infections may contribute (23) (24) (25) . Rates of prostate, breast, and colon cancer are actually lower in PLWH in some studies (9, 21) .
Between 2000 and 2012, we observed stable or decreasing incidence rates for most types of NADC, except prostate cancer among men aged 35 to 64 years. These trends are generally consistent with those reported in other recent studies (5, 26, 27) . Furthermore, the risks for anal, lung, and liver cancer and Hodgkin lymphoma in U.S. PLWH have declined relative to those in the general population, supporting a role of ART in decreasing risk for these types of cancer (9) . Of note, we project that rates of lung cancer will no longer be elevated among PLWH by 2030. Although lung cancer rates have declined significantly, we caution that our projection of a continued decline may not be realistic if the prevalence of smoking does not decrease substantially among PLWH (22) .
Quantifying both incidence rates and burden is important. Rates describe cancer risk among PLWH, whereas burden captures total number of diagnoses. Changes in incidence rates, population age structure, and population size all influence cancer burden. By holding the incidence rates or age structure constant on the basis of 2012 estimates in secondary analyses, we could assess how changes over time contributed to the projections in our main analyses. Decreasing incidence rates most notably affected the decreasing burden of KS, NHL, and cervical cancer. In contrast, the aging of U.S. PLWH resulted in a projected increase for many cancer types, most notably prostate and lung cancer. Although the cancer burden is projected to evolve, it will continue to differ from that in the general population, with a higher fraction of KS, liver cancer, and anal cancer.
The main strengths of this analysis were the data sources, which included high-quality data on cancer in- 
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cidence in nearly 500 000 PLWH and U.S. HIV population estimates from the HOPE model developed by the Centers for Disease Control and Prevention. Our results should be interpreted under the assumption that current trends in cancer incidence, HIV transmission, and survival will continue through 2030, which we largely attribute to improvements in and wider use of ART. Of note, our analysis cannot account for any unexpected changes in HIV or cancer incidence. For example, interventions that have been recently introduced or may expand in the coming years could reduce future cancer risk and burden in PLWH (such as treatment of hepatitis C virus infection and screening for anal cancer). In contrast, unforeseen changes that reduce access to treatment of HIV infection (such as reductions in health insurance coverage) or increase HIV incidence (such as outbreaks due to increases in injection drug use) would increase the cancer burden among PLWH. The main limitation is the uncertainty in the input parameters of the HOPE model, although modeled estimates closely matched HIV surveillance estimates for 2014 (28) . For example, the latest 2014 estimates from the Centers for Disease Control and Prevention for persons aged 13 to 64 years were 1 107 700 cases for overall HIV prevalence and 37 600 cases for overall HIV incidence (28) , and the model predictions were 1 042 140 and 35 761 cases, respectively, suggesting some predictive validity. We did uncertainty analyses by varying the calibrated parameters, and those results indicated robustness in prevalence estimates across potential calibration sets. We have attempted to quantify the uncertainty around our cancer burden estimates by combining information on the uncertainties in rate and population projections. In addition, power was limited for several strata, which may have resulted in trends being modeled as flat projections.
Although the number of cancer cases diagnosed among PLWH is projected to decrease, cancer will remain an important comorbid condition, and continued prevention efforts are needed. Increased access to effective ART will be critical in reducing future cancer burden in PLWH, and current recommendations advocate treatment of all PLWH, regardless of CD4 count (29). Interventions focused on smoking cessation and treatment of hepatitis B and C virus infections could reduce the future burden of lung and liver cancer. Vaccination for HPV has been found to be safe and immunogenic in PLWH (30) , and a clinical trial is currently evaluating vaccination in HIV-infected MSM for the prevention of HPV infection and anal intraepithelial neoplasia (ClinicalTrials.gov: NCT01209325).
Future research and public health programs should also focus on early detection and treatment of cancer among PLWH. Some screen-detectable types (such as breast, lung, and cervical cancer) are more frequently diagnosed at advanced stages among PLWH, perhaps reflecting delayed diagnosis (31) . Specific cervical cancer screening guidelines should be followed for HIVinfected women (32). For other types of cancer, screening strategies in PLWH receiving ART should reflect the same consideration of benefits, harms, and costs as in the general population. Of note, an ongoing clinical trial is addressing anal Papanicolaou testing and treatment of precancerous lesions among PLWH (ClinicalTrials.gov: NCT 02135419), and more research is needed on screening for lung cancer (low-dose computed tomography). Fi- Cancer burden estimates for 2030 were calculated 3 ways: using the 2030 projected cancer incidence rates and 2030 projected age structure, using the 2012 modeled cancer incidence rates and 2030 projected age structure, and using the 2030 projected cancer incidence rates and 2012 modeled age structure. KS = Kaposi sarcoma; NHL = non-Hodgkin lymphoma.
Cancer Projections in HIV-Infected U.S. Adults Through 2030 ORIGINAL RESEARCH nally, cancer treatment and survival differ between PLWH and the general population, which emphasizes the need to incorporate PLWH into clinical trials and guidelines for cancer treatment (33) (34) (35) .
In conclusion, we have shown that the number of incident cancer diagnoses (that is, cancer burden) among PLWH will shift substantially through 2030. The incidence rates of most cancer types will likely remain stable or decrease, with the largest declines for NHL and KS. In 2030, prostate and lung cancer are projected to be the most common types, followed by liver and anal cancer. Although the total burden of cancer among PLWH is expected to decrease by 18%, cancer will remain an important comorbid condition, and tailored public health programs focused on cancer prevention, screening, and treatment in PLWH are needed. HIV-uninfected and HIV-infected populations between compartments. Differential equations in the model are solved using MATLAB software (MathWorks). Additional model details, including definitions of all subpopulations and compartments and descriptions of differential equations; force-of-infection calculations; inputs and sources; calibration; validation; and other methods, assumptions, and specifications, are published in a full technical report on the HOPE model (14, 15) . This model assumes that no new infections occur among or are caused by persons older than 65 years. The HOPE model has been shown to closely match published HIV surveillance estimates. For example, the latest 2014 estimates from the Centers for Disease Control and Prevention for persons aged 13 to 64 years were 1 107 700 cases for overall HIV prevalence and 37 600 cases for overall HIV incidence (28) , and the model predictions were 1 042 140 and 35 761 cases, respectively.
To consider the uncertainty of the HIV prevalence for 2006 to 2030 due to the values of the parameters, we ran the HOPE model using 10 additional sets of values for those inputs that, like the set used in the base-case analysis, approximated the targeted surveillance measures. To generate each of the 10 sets, we went through a calibration process, which was also used to generate the base-case inputs. The process that was applied to calibrate the model is outlined in sections 11.1.1 to 11.1.4 of the published technical report (15) . We report the range of the HIV population estimates across those runs. 
